Statements (18)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:focus |
oncology
cardiovascular diseases central nervous system disorders |
| gptkbp:founded |
2001
|
| gptkbp:founder |
Chang H. Ahn
|
| gptkbp:headquarters_location |
gptkb:Rockville,_Maryland,_United_States
|
| gptkbp:industry |
gptkb:biotechnology
|
| gptkbp:mergedInto |
2020
Ocuphire Pharma |
| gptkbp:pipeline |
RX-0301
RX-3117 RX-5902 |
| gptkbp:tradedOn |
NASDAQ: REXN
|
| gptkbp:website |
www.rexahn.com
|
| gptkbp:bfsParent |
gptkb:RXC007
|
| gptkbp:bfsLayer |
8
|
| https://www.w3.org/2000/01/rdf-schema#label |
Rexahn Pharmaceuticals
|